Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04

被引:166
|
作者
Varasteh, Zohreh [1 ]
Mohanta, Sarajo [2 ,3 ]
Robu, Stephanie [1 ]
Braeuer, Miriam [1 ]
Li, Yuanfang [2 ]
Omidvari, Negar [1 ]
Topping, Geoffrey [1 ]
Sun, Ting [2 ]
Nekolla, Stephan G. [1 ]
Richter, Antonia [1 ]
Weber, Christian [2 ,3 ]
Habenicht, Andreas [2 ]
Haberkorn, Uwe A. [4 ]
Weber, Wolfgang A. [1 ]
机构
[1] Klinikum Rechts Isar TUM, Dept Nucl Med, Ismaningerstr 22, D-81675 Munich, Germany
[2] Ludwig Maximilians Univ Munchen, Inst Cardiovasc Prevent, Munich, Germany
[3] Munich Heart Alliance, German Ctr Cardiovasc Res, Munich, Germany
[4] Heidelberg Univ, Dept Nucl Med, Heidelberg, Germany
关键词
myocardial infarction; cardiac remodeling; fibroblast activation protein; molecular imaging; PET; EXPRESSION; INTEGRIN; ALPHA(V)BETA(3); FIBROSIS;
D O I
10.2967/jnumed.119.226993
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Heart failure remains a major source of late morbidity and mortality after myocardial infarction (MI). The temporospatial presence of activated fibroblasts in the injured myocardium predicts the quality of cardiac remodeling after MI. Therefore, monitoring of activated fibroblasts is of great interest for studying cardiac remodeling after MI. Fibroblast activation protein (FAP) expression is upregulated in activated fibroblasts. This study investigated the feasibility of imaging activated fibroblasts with a new Ga-68-labeled FAP inhibitor (Ga-68-FAPI-04) for PET imaging of fibroblast activation in a preclinical model of MI. Methods: MI and sham-operated rats were scanned with Ga-68-FAPI-04 PET/CT (1, 3, 6, 14, 23, and 30 d after MI) and with F-18-FDG (3 d after MI). Dynamic Ga-68-FAPI-04 PET and blocking studies were performed on MI rats 7 d after coronary ligation. After in vivo scans, the animals were euthanized and their hearts harvested for ex vivo analyses. Cryosections were prepared for autoradiography, hematoxylin and eosin (H&E), and immunofluorescence staining. Results: Ga-68-FAPI-04 uptake in the injured myocardium peaked on day 6 after coronary ligation. The tracer accumulated intensely in the MI territory, as identified by decreased F-18-FDG uptake and confirmed by PET/MR and H&E staining. Autoradiography and H&E staining of cross-sections revealed that Ga-68-FAPI-04 accumulated mainly at the border zone of the infarcted myocardium. In contrast, there was only minimal uptake in the infarct of the blocked rats, comparable to the uptake in the remote noninfarcted myocardium (PET image-derived ratio of infarct uptake to remote uptake: 6 +/- 2). Immunofluorescence staining confirmed the presence of FAP-positive myofibroblasts in the injured myocardium. Morphometric analysis of the whole-heart sections demonstrated 3- and 8-fold higher FAP-positive fibroblast density in the border zone than in the infarct center and remote area, respectively. Conclusion: Ga-68-FAPI-04 represents a promising radiotracer for in vivo imaging of post-MI fibroblast activation. Noninvasive imaging of activated fibroblasts may have significant diagnostic and prognostic value, which could aid clinical management of patients after MI.
引用
收藏
页码:1743 / 1749
页数:7
相关论文
共 50 条
  • [31] Cardiac fibroblast activation detected by Ga-68 FAPI PET imaging as a potential novel biomarker of cardiac injury/remodeling
    J. Siebermair
    M. I. Köhler
    J. Kupusovic
    S. G. Nekolla
    L. Kessler
    J. Ferdinandus
    N. Guberina
    M. Stuschke
    H. Grafe
    J. T. Siveke
    S. Kochhäuser
    W. P. Fendler
    M. Totzeck
    R. Wakili
    L. Umutlu
    T. Schlosser
    T. Rassaf
    C. Rischpler
    Journal of Nuclear Cardiology, 2021, 28 : 812 - 821
  • [32] Clinical prospective study of Gallium 68 (68Ga)-labeled fibroblast-activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma
    Li, Jinghua
    Xu, Kui
    Guo, Deliang
    Liao, Bo
    Zhu, Qian
    Wang, Haitao
    Jiang, Yaqun
    Wu, Dongde
    Xia, Xigang
    Jiang, Ping
    Tang, Shengli
    Yang, Zhiyong
    He, Yueming
    Zhang, Zhonglin
    He, Yong
    Yuan, Yufeng
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (07) : 2152 - 2166
  • [33] Clinical prospective study of Gallium 68 (68Ga)–labeled fibroblast-activation protein inhibitor PET/CT in the diagnosis of biliary tract carcinoma
    Li Jinghua
    Xu Kui
    Guo Deliang
    Liao Bo
    Zhu Qian
    Wang Haitao
    Jiang Yaqun
    Wu Dongde
    Xia Xigang
    Jiang Ping
    Tang Shengli
    Yang Zhiyong
    He Yueming
    Zhang Zhonglin
    He Yong
    Yuan Yufeng
    European Journal of Nuclear Medicine and Molecular Imaging, 2023, 50 : 2152 - 2166
  • [34] The Role of Fibroblast Activation Protein in Glioblastoma and Gliosarcoma: A Comparison of Tissue, 68 Ga-FAPI-46 PET Data, and Survival Data
    Oster, Christoph
    Kessler, Lukas
    Blau, Tobias
    Keyvani, Kathy
    Pabst, Kim M.
    Fendler, Wolfgang P.
    Costa, Pedro Fragoso
    Lazaridis, Lazaros
    Schmidt, Teresa
    Feldheim, Jonas
    Pierscianek, Daniela
    Schildhaus, Hans Ulrich
    Sure, Ulrich
    Ahmadipour, Yahya
    Kleinschnitz, Christoph
    Guberina, Nika
    Stuschke, Martin
    Deuschl, Cornelius
    Scheffler, Bjoeurorn
    Herrmann, Ken
    Kebir, Sied
    Glas, Martin
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65 (08) : 1217 - 1223
  • [35] Heterogeneity of fibroblast activation protein expression in the microenvironment of an intracranial tumor cohort: head-to-head comparison of gallium-68 FAP inhibitor-04 (68Ga-FAPi-04) 68 Ga-FAPi-04) and fluoride-18 fluoroethyl-L-tyrosine (18F-FET) 18 F-FET) in positron emission tomography-computed tomography imaging
    Hua, Tao
    Chen, Mingyu
    Fu, Pengfei
    Zhou, Weiyan
    Zhao, Wen
    Li, Ming
    Zuo, Chuantao
    Guan, Yihui
    Xu, Hongzhi
    QUANTITATIVE IMAGING IN MEDICINE AND SURGERY, 2024, 14 (07) : 4450 - 4463
  • [36] A clinical study on relationship between visualization of cardiac fibroblast activation protein activity by Al18F-NOTA-FAPI-04 positron emission tomography and cardiovascular disease
    Lyu, Zhehao
    Han, Wei
    Zhao, Hongyue
    Jiao, Yuying
    Xu, Peng
    Wang, Yangyang
    Shen, Qiuyi
    Yang, Shuai
    Zhao, Changjiu
    Tian, Lin
    Fu, Peng
    FRONTIERS IN CARDIOVASCULAR MEDICINE, 2022, 9
  • [37] A Simple Kit Formulation for Preparation and Exploratory Human Studies of a Novel 99mTc-Labeled Fibroblast Activation Protein Inhibitor Tracer for Imaging of the Fibroblast Activation Protein in Cancers
    Ruan, Qing
    Zhou, Cheng
    Wang, Qianna
    Kang, Fei
    Jiang, Yuhao
    Li, Guoquan
    Feng, Junhong
    Zong, Shu
    Zhang, Junbo
    Wang, Jing
    MOLECULAR PHARMACEUTICS, 2023, 20 (06) : 2942 - 2950
  • [38] Evaluation of a Novel Gd-FAPI Dimer Molecular Probe Targeting Fibroblast Activation Protein for Imaging of Solid Tumors
    Wang, Xiaohui
    Zhuang, Caiyu
    Zheng, Xinhui
    Zhang, Xiaolei
    Han, Zhijian
    Wu, Renhua
    MOLECULAR PHARMACEUTICS, 2025, 22 (03) : 1498 - 1506
  • [39] Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor-Directed Molecular Imaging and Therapy
    Serfling, Sebastian E.
    Hartrampf, Philipp E.
    Zhi, Yingjun
    Higuchi, Takahiro
    Rowe, Steven P.
    Bundschuh, Lena
    Essler, Markus
    Buck, Andreas K.
    Bundschuh, Ralph Alexander
    Werner, Rudolf A.
    CLINICAL NUCLEAR MEDICINE, 2022, 47 (06) : 512 - 516
  • [40] Fibroblast activation protein imaging in reperfused ST-elevation myocardial infarction: comparison with cardiac magnetic resonance imaging
    Xie, Boqia
    Wang, Jiaxin
    Xiao-Ying Xi
    Guo, Xiaojuan
    Bi-Xi Chen
    Li, Lina
    Hua, Cuncun
    Zhao, Shihua
    Su, Pixiong
    Chen, Mulei
    Min-Fu Yang
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2022, 49 (08) : 2786 - 2797